Cellectar, an OTC Stock, Eyes Nasdaq Jump to Boost Profile, Prospects – Xconomy
|
Cellectar, an OTC Stock, Eyes Nasdaq Jump to Boost Profile, Prospects
Xconomy Winning approval to join the Nasdaq stock exchange could give Cellectar a boost in bringing its cancer drugs and imaging products to market—assuming the company can capitalize on the opportunity. And at the very least, Cellectar would raise its … |
